Celltrion to cut Remsima price by 50% for low-income households

Published: 2012-10-15 06:56:00

Updated: 2012-10-15 06:56:00

Celltrion, a local biopharmaceutical company, said it will cut the insurance price of its antibody biosimilar product “Resima” by 50 percent for low-income patients who are not covered by the national health insurance scheme.

To this end, Celltrion signed an agreement with the Korea Medical As...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK